Anticoagulation Duration in Pulmonary Embolism
Initial Anticoagulation Duration
- The European Society of Cardiology recommends that all patients with pulmonary embolism (PE) should receive therapeutic anticoagulation for at least 3 months, regardless of etiology 1, 2
- For patients with first PE secondary to a major transient/reversible risk factor, discontinuation of therapeutic oral anticoagulation is recommended after 3 months, as suggested by the European Society of Cardiology 1, 2
- The International Society on Thrombosis and Haemostasis suggests that for patients with unprovoked PE or proximal DVT, initial anticoagulation should be administered for 3 to 6 months 3, 4
- For patients with unprovoked isolated calf DVT, 3 months of anticoagulation is suggested by the International Society on Thrombosis and Haemostasis 3, 5
Extended Anticoagulation Recommendations
- The European Society of Cardiology recommends oral anticoagulant treatment of indefinite duration for patients with recurrent VTE (at least one previous episode of PE or DVT) not related to a major transient or reversible risk factor 1, 2
- Extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE and no identifiable risk factor, as recommended by the European Society of Cardiology 1, 2
- The European Society of Cardiology also recommends that extended oral anticoagulation of indefinite duration should be considered for patients with a first episode of PE associated with a persistent risk factor other than antiphospholipid antibody syndrome 1, 2
- Oral anticoagulant treatment with a VKA for an indefinite period is recommended for patients with antiphospholipid antibody syndrome by the European Society of Cardiology 1, 2
Risk Stratification for Recurrence
- The International Society on Thrombosis and Haemostasis states that the circumstances in which PE occurs is the strongest predictor of recurrence risk 3, 5
- Patients with unprovoked venous thrombosis have an annual risk of recurrence >5%, which exceeds the risk of VKA-related bleeding, according to the International Society on Thrombosis and Haemostasis 3, 5
- The International Society on Thrombosis and Haemostasis suggests that patients with PE provoked by surgery are at low risk of recurrence (annual risk <1%) after completing 3 months of treatment 3, 5
- Patients with PE associated with non-surgical risk factors have an intermediate risk of recurrence, as stated by the International Society on Thrombosis and Haemostasis 3, 5
Special Considerations
- If extended oral anticoagulation is decided after PE in a patient without cancer, a reduced dose of NOACs (apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily) should be considered after 6 months of therapeutic anticoagulation, as recommended by the European Society of Cardiology 1, 2
- In patients who receive extended anticoagulation, it is recommended to reassess drug tolerance and adherence, hepatic and renal function, and bleeding risk at regular intervals, according to the European Society of Cardiology 1, 6, 7
Common Pitfalls and Caveats
- Failing to recognize that the benefit of anticoagulation continues only for as long as therapy is continued, as noted by the International Society on Thrombosis and Haemostasis 8, 3
- Not considering the individual patient's bleeding risk when determining duration of anticoagulation, as recommended by the European Society of Cardiology 1, 2
- Overlooking that extended anticoagulation may equate to lifelong treatment, or until the perceived risk of bleeding becomes prohibitive, as stated by the International Society on Thrombosis and Haemostasis 8, 4
- Not routinely re-evaluating patients 3-6 months after acute PE to assess for chronic complications and determine the appropriate duration of anticoagulation, as recommended by the European Society of Cardiology 6, 7
Minimum Duration of Anticoagulation for Acute Pulmonary Embolism
Initial Mandatory Anticoagulation
- All patients with acute pulmonary embolism should receive therapeutic anticoagulation for at least 3 months; this is a Class I recommendation of the European Society of Cardiology, reflecting strong evidence. 9
- The 3‑month minimum is required to prevent thrombus extension and early recurrence of embolic events. 10
Decision After the First 3 Months
Provoked Pulmonary Embolism (major transient/reversible risk factor)
- If the embolism was secondary to a major transient risk factor (e.g., surgery), anticoagulation may be stopped after 3 months. 9
Unprovoked (Idiopathic) Pulmonary Embolism
- For unprovoked embolism, indefinite anticoagulation should be considered when the individual’s bleeding risk is judged low‑to‑moderate. 9
Recurrent Pulmonary Embolism
- Patients with a history of prior pulmonary embolism or deep‑vein thrombosis (i.e., recurrent disease) should receive indefinite anticoagulation, regardless of transient risk factors. 9
Choice of Anticoagulant
- Prefer direct oral anticoagulants (NOACs)—apixaban, rivaroxaban, edoxaban, or dabigatran—over vitamin K antagonists when initiating oral therapy. This recommendation is based on the European Society of Cardiology guidance. 9
- Avoid NOACs in patients with severe renal impairment or antiphospholipid syndrome. 9
- In the setting of antiphospholipid syndrome, a vitamin K antagonist should be used indefinitely. 9
Follow‑up and Re‑assessment
- Routine re‑evaluation of all patients should occur 3–6 months after the acute event to assess treatment response and safety. 9
- For patients on extended anticoagulation, conduct annual reviews focusing on drug tolerance, adherence, hepatic and renal function, and bleeding risk. 11